$3.85
2.53% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US67092M2089
Symbol
NTRB
Sector

Nutriband Stock price

$3.85
-1.00 20.62% 1M
-1.49 27.90% 6M
+1.53 65.95% YTD
+0.87 29.02% 1Y
+0.77 25.12% 3Y
-8.15 67.92% 5Y
-1.81 31.94% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.10 2.53%
ISIN
US67092M2089
Symbol
NTRB
Sector

Key metrics

Market capitalization $42.76m
Enterprise Value $37.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 18.45
P/S ratio (TTM) P/S ratio 21.17
P/B ratio (TTM) P/B ratio 3.81
Revenue growth (TTM) Revenue growth -3.18%
Revenue (TTM) Revenue $2.02m
EBIT (operating result TTM) EBIT $-6.03m
Free Cash Flow (TTM) Free Cash Flow $-4.25m
Cash position $5.70m
EPS (TTM) EPS $-0.71
Short interest 1.00%
Show more

Is Nutriband a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Nutriband Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Nutriband:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Nutriband:

Buy
100%

Financial data from Nutriband

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Oct '24
+/-
%
2.02 2.02
3% 3%
100%
- Direct Costs 1.43 1.43
9% 9%
71%
0.59 0.59
24% 24%
29%
- Selling and Administrative Expenses 3.15 3.15
15% 15%
156%
- Research and Development Expense 3.19 3.19
89% 89%
158%
-5.75 -5.75
24% 24%
-285%
- Depreciation and Amortization 0.28 0.28
7% 7%
14%
EBIT (Operating Income) EBIT -6.03 -6.03
23% 23%
-299%
Net Profit -6.85 -6.85
30% 30%
-339%

In millions USD.

Don't miss a Thing! We will send you all news about Nutriband directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nutriband Stock News

Neutral
GlobeNewsWire
one day ago
Nutriband's abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets. Nutriband is targeting to file for FDA approval for AVERSA™ Fentanyl in the first half of 2025.
Neutral
GlobeNewsWire
25 days ago
ORLANDO, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today reported its financial results for the third quarter ended October 31, 2024.
Neutral
GlobeNewsWire
about one month ago
ORLANDO, Fla., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received a Notice of Publication of the Registration and Grant of a Standard Patent (R) from the Hong Kong Intellectual Property Department for patent application entitled, “Abuse and Mi...
More Nutriband News

Company Profile

Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. It delivers abuse deterrent fentanyl transdermal system which provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. It operates through the Pocono Coated Products and Active Intelligence segments. The company was founded by Gareth R. Sheridan and Serguei Melnik in 2016 and is headquartered in Orlando, FL.

Head office United States
CEO Gareth Sheridan
Founded 2012
Website www.nutriband.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today